CD19 and precursor B-cell acute lymphoblastic leukemia: In the phase 1 trial of a CD19-4-1BB-ζ CAR for pediatric B-ALL, 13 of 55 patients (24%) had a CD19-negative relapse after achieving a prior CR (72).